A phase I/IIa, open-label, three-stage, study to investigate the safety, the efficacy and the pharmacokinetics of Niclosamide enemas in subjects with active Ulcerative Proctitis or Ulcerative Procto-Sigmoiditis

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niclosamide (Primary)
Indications Ulcerative proctitis; Ulcerative proctosigmoiditis
Focus Adverse reactions; First in man
Sponsors Entero Therapeutics; First Wave Bio

Most Recent Events

16 May 2024 According to an Entero Therapeutics media release, First Wave Biopharma has changed its name to Entero Therapeutics.
28 Nov 2022 Status changed from active, no longer recruiting to discontinued.
20 Oct 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight